Theravance (THRX) Reports Q1 Loss of $0.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Theravance Reports First Quarter 2015 Financial Results
May 6, 2015 4:05 PM EDTSOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/06/15 -- Theravance, Inc. (NASDAQ: THRX) today reported financial results for the first quarter ended March 31, 2015. Royalties earned on net sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA from Glaxo Group Limited (GSK) during the first quarter 2015 were $10.1 million, and income from operations increased to $0.7 million, compared to $0.1 million in the fourth quarter of 2014. Adjusted EBITDA for the first quarter of 2015 was $6.2 million. Net loss for the first quarter 2015 was $10.7 million or $0.09 per share. Cash and cash equivalents, short-term investments, and marketable securities totaled $255.1 million as of March 31,... More
